Business
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
Patent provides added depth to Enveric’s EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of
About this update from Enveric Biosciences, Inc.
[{"type":"text","content":"\nPatent provides added depth to Enveric’s EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nEnveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that on March 17, 2026, it received U.S. Patent No. 12,577,232 (“the’232 patent”) from the United States Patent and Trademark Office (USPTO) pertaining to its EVM301 Series of molecules. The EVM301 Series includes lead candidate, EB-003, being developed as potential treatments for mental health disorders.\n\n\nEntitled, “N-heterocycle substituted tryptamine derivatives and methods of using,” the patent adds to the portfolio covering Enveric’s EVM301 Series of molecules. The issued patent claims chemical compounds, pharmaceutical drug formulations, and methods for treating brain neurological disorders. The ‘232 patent enhances the patent claim coverage of Enveric’s N-heterocycle substituted tryptamine derivative molecules which are also the subject of previously issued U.S. Patent No. 12,338,231. Enveric’s EVM301 Series of molecules include potential neuroplastogenic non-hallucinogenic molecules intended to target neuropsychiatric and addiction disorders for patients with limited options.\n\n\n“We are very pleased with this new U.S. patent issuance as we continue to work diligently to reinforce our EVM301 Series intellectual property estate and generate additional value for Enveric stockholders,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “Our company remains focused on advancing EB-003 toward submitting an IND application to the FDA and initiating a first-in-human Phase 1 clinical trial.”\n\n\nEB-003 is Enveric’s lead neuroplastogen, designed as a 5-HT2A / 5-HT1B dual-acting compound with the potential to address depression and anxiety by promoting neuroplastic changes without hallucinogenic effects. Enveric’s pipeline is supported by its broad patent estate, which includes 27 issued U.S. patents and approximately 60 pending national and international applications covering multiple differentiated molecules.\n\n\nAbout Enveric Biosciences\n\n\nEnveric Biosciences (NASDAQ: ENVB) i...